Radiation Oncology Unit, Department of Radiology, Radiation Oncology and Hematology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Radiotherapy Department, Santa Maria Goretti Hospital, Latina, Italy.
Clin Transl Oncol. 2024 Mar;26(3):644-652. doi: 10.1007/s12094-023-03289-0. Epub 2023 Jul 29.
The Re-irradiation and the Breast Cancer Working Groups of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) conducted a survey to provide an overview of the policies for breast cancer (BC) re-irradiation (re-RT) among the Italian radiotherapy (RT) centers.
In October 2021, 183 RT centers were invited to answer a survey: after an initial section about general aspects, the questionnaire focused on radiation oncologists' (ROs) attitude toward re-RT in three different scenarios: ipsilateral breast tumor recurrence (IBTR) treated with second conservative surgery, IBTR treated with mastectomy and inoperable IBTR. Surveyed ROs were also asked to express their interest in being involved in a prospective trials.
Seventy-seven/183 (42.0%) centers answered the Survey, only one RO per center was requested to answer. In particular, 86.5% ROs declared to have performed "curative" re-RT for IBTR during the previous two years (2019-2020): 76.7% respondents administered re-RT after second BCS, 50.9% after mastectomy, and 48.1% for inoperable IBTR. Re-RT practice varied widely among centers in terms of treatment volumes, dose and fractionation schedules, techniques and dose-volume constraints for organs at risks (OARs). Forty-six participants (59.7%) expressed their interest in participating in a prospective study investigating BC re-RT.
About one out of three RT centers in Italy delivered re-RT for IBTR. Nevertheless, practice of re-RT varied widely among centers highlighting the needs for prospective studies to improve knowledge in this field.
意大利放射肿瘤学和临床肿瘤学协会（AIRO）的再放疗和乳腺癌工作组进行了一项调查，以概述意大利放射治疗（RT）中心对乳腺癌（BC）再放疗（re-RT）的政策。
2021 年 10 月，邀请了 183 个 RT 中心回答一项调查：在最初关于一般方面的部分之后，调查问卷集中在放射肿瘤学家（RO）在三种不同情况下对 re-RT 的态度：同侧乳房肿瘤复发（IBTR）接受第二次保乳手术、IBTR 接受乳房切除术和不可手术的 IBTR。还要求接受调查的 RO 表达他们参与前瞻性试验的兴趣。
77/183（42.0%）个中心回答了调查，每个中心只要求一名 RO 回答。特别是，86.5%的 RO 报告在过去两年（2019-2020 年）中对 IBTR 进行了“治愈性”re-RT：76.7%的受访者在第二次 BCS 后进行了 re-RT，50.9%在乳房切除术后，48.1%用于不可手术的 IBTR。在治疗体积、剂量和分割方案、技术和危及器官（OARs）剂量-体积限制方面，中心之间的 re-RT 实践差异很大。46 名参与者（59.7%）表示有兴趣参与一项前瞻性研究，研究 BC 的 re-RT。
意大利约有三分之一的 RT 中心为 IBTR 提供 re-RT。然而，re-RT 的实践在中心之间差异很大，突出了需要前瞻性研究来提高该领域的知识。
